(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…
Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120096
Author :
Publish date : 2026-02-27 22:43:00
Copyright for syndicated content belongs to the linked Source.
